标题
Combination therapy patents: a new front in evergreening
作者
关键词
-
出版物
NATURE BIOTECHNOLOGY
Volume 39, Issue 12, Pages 1504-1510
出版商
Springer Science and Business Media LLC
发表日期
2021-12-09
DOI
10.1038/s41587-021-01137-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma
- (2021) Simon Chowdhury et al. Clinical Genitourinary Cancer
- Identifying potential prescription drug product hopping
- (2021) Vrushab Gowda et al. NATURE BIOTECHNOLOGY
- Registration trials in countries without access to US standards of care — pitfalls of interpretation
- (2021) Garth W. Strohbehn et al. Nature Reviews Clinical Oncology
- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
- (2020) Paola Ciciola et al. Journal of Clinical Medicine
- Opportunities for using In Silico ‐Based Extended Dosing Regimens for Monoclonal Antibody Immune Checkpoint Inhibitors
- (2020) Cody J. Peer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- 702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
- (2020) S. Pal et al. ANNALS OF ONCOLOGY
- LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
- (2020) Z. Lwin et al. ANNALS OF ONCOLOGY
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
- (2020) A.M. Arance Fernandez et al. ANNALS OF ONCOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Tertiary patenting on drug–device combination products in the United States
- (2018) Reed F Beall et al. NATURE BIOTECHNOLOGY
- Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology
- (2018) Bruno Kovic et al. JAMA Internal Medicine
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Combining drugs and extending treatment — a PFS end point is not sufficient
- (2017) Bishal Gyawali et al. Nature Reviews Clinical Oncology
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
- (2015) Chul Kim et al. JAMA Internal Medicine
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- The misguided ethics of crossover trials
- (2013) Vinay Prasad et al. Contemporary Clinical Trials
- Evergreening: a common practice to protect new drugs
- (2011) Kate S Gaudry NATURE BIOTECHNOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search